COMP <GO>
CRMD vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
CorMedix Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CRMD 7
— JNJ 3
■ METRIC PARITY
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
options-implied-move
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 67.90% | +20.60 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | 25.50% | +20.00 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 18.5x | -15.50 | CRMD | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | 34.70% | +13.50 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | 28.50% | +23.80 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 5.59 | -3.78 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.6 | 62.1 | -11.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 23.0x | -19.50 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $662.49B | -$661.90B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | JNJ REV | CRMD GROSS % | JNJ GROSS % | CRMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $94.19B | 88.5% | 67.9% | $172.8M | $19.70B |
| FY 2024 | $43.5M | $88.82B | 92.7% | 69.1% | -$50.7M | $19.84B |
| FY 2023 | $0 | $85.16B | — | — | -$38.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
JNJ // BETA 1.08